BACKGROUND: More than 1.5 million women per year have a benign breast biopsy resulting in concern about their future breast cancer (BC) risk. This study examined the performance of 2 BC risk models that integrate clinical and histologic findings in this population. METHODS: The BC risk at 5 and 10 years was estimated with the Breast Cancer Surveillance Consortium (BCSC) and Benign Breast Disease to Breast Cancer (BBD-BC) models for women diagnosed with benign breast disease (BBD) at the Mayo Clinic from 1997 to 2001. Women with BBD were eligible for the BBD-BC model, but the BCSC model also required a screening mammogram. Calibration and discrimination were assessed. RESULTS: Fifty-six cases of BC were diagnosed among the 2142 women with BBD (median age, 50 years) within 5 years (118 were diagnosed within 10 years). The BBD-BC model had slightly better calibration at 5 years (0.89; 95% confidence interval [CI], 0.71-1.21) versus 10 years (0.81; 95% CI, 0.70-1.00) but similar discrimination in the 2 time periods: 0.68 (95% CI, 0.60-0.75) and 0.66 (95% CI, 0.60-0.71), respectively. In contrast, among the 1089 women with screening mammograms (98 cases of BC within 10 years), the BCSC model had better calibration (0.94; 95% CI, 0.85-1.43) and discrimination (0.63; 95% CI, 0.56-0.71) at 10 years versus 5 years (calibration, 1.31; 95% CI, 0.94-2.25; discrimination, 0.59; 95% CI, 0.46-0.71) where discrimination was not different from chance. CONCLUSIONS: The BCSC and BBD-BC models were validated in the Mayo BBD cohort, although their performance differed by 5-year risk versus 10-year risk. Further enhancement of these models is needed to provide accurate BC risk estimates for women with BBD.
INTRODUCTION
As part of early detection efforts for breast cancer (BC), more than 1.6 million breast biopsies are performed on women every year within the United States. 1 Many women with a confirmed benign biopsy or benign breast disease (BBD) have been shown to be at increased risk for future BC; this ranges from population risk for those diagnosed with nonproliferative disease (NP) to above-average risk for those with proliferative disease without atypia (PDWA) to 4-fold increased risk for those with atypical hyperplasia (AH). 2 Being able to provide accurate risk estimates in this population is important. 2 The most widely used BC risk-prediction tool is the Breast Cancer Risk Assessment Tool (BCRAT), which identifies groups of women at increased risk, but it has limited accuracy in predicting risk for individual women [3] [4] [5] and has been shown to be ineffective at predicting risk in women with AH. 6 The only pathologic risk factor included in the BCRAT is the presence of AH. The recently developed Benign Breast Disease to Breast Cancer (BBD-BC) model, developed in the Mayo BBD cohort, 2 uses clinical risk factors and pathologic features from the benign biopsy, including age-related lobular involution, to predict the future risk of either invasive BC or ductal carcinoma in situ (DCIS) after BBD, and it has demonstrated greater accuracy than the BCRAT in this setting. 7 The Breast Cancer Surveillance Consortium (BCSC) riskprediction model was developed to estimate the risk of incident invasive BC in screened populations by incorporating breast density according to Breast Imaging Reporting and Data System (BI-RADS) criteria along with other epidemiologic risk factors. The BCSC model was also shown to be more accurate than the BCRAT. 8 Recently, the BCSC model was updated to include prior diagnoses of BBD.
The BCSC model was previously validated in a mammography screening cohort, the Mayo Mammography Health Study, 10 but it has not been evaluated in a cohort composed exclusively of women with BBD. The BBD-BC model has not been examined outside the model development and validation studies. 7 This study assesses the performance of both models in an independent sample from the Mayo Clinic's BBD cohort.
MATERIALS AND METHODS

Study Sample
The Mayo Clinic BBD cohort has been described previously and currently includes 13,528 women aged 18 to 85 years who underwent a benign breast biopsy between 1967 and 2001 at the Mayo Clinic in Rochester, Minnesota. 2, 11 Clinical risk factors, demographics, and followup for BC were identified from questionnaires and medical records, which included the family history of BC, the age of first live birth, and the number of children.
Each woman was retrospectively followed forward in time from the date of biopsy to the first occurrence of a BC diagnosis (invasive or DCIS), prophylactic mastectomy, death, or the date of last contact, as determined via the electronic or manual abstraction of medical records, billing data, and mailed questionnaires, as described previously. 2 Women with less than 6 months of follow-up were excluded.
Women from the BBD cohort with an initial benign biopsy between 1997 and 2001 form the study group used in the current analysis. 7 Because the original BBD-BC model was developed in women diagnosed from 1967 to 1991, this more recent group is mutually exclusive from prior modeling activities and thus is suitable for independent validation for both the BBD-BC and BCSC models. 7 Also, because the BCSC model incorporates BI-RADS density, which was not used clinically at the Mayo Clinic until 1997, we have excluded women with initial biopsies between 1992 and 1996. This study was approved by the Mayo Clinic Institutional Review Board.
Eligibility criteria differ between the 2 models. First, the BCSC model includes women with lobular carcinoma in situ (LCIS) and categorizes them as having benign disease, whereas the BBD-BC model excludes women with LCIS at initial biopsy and censors women at the time of LCIS diagnosis at subsequent biopsy. Second, the BCSC model is intended for women who have undergone mammography and have corresponding BI-RADS density measures, whereas the BBD-BC model includes women not undergoing mammography or having missing density values. Third, the BCSC model is restricted to women aged 35 to 74 years, whereas the BBD-BC model includes women aged 18 to 85 years. Finally, the BCSC model predicts only women with invasive cancer as an event, whereas the BBD-BC model includes a diagnosis of DCIS in its case definition. To fairly evaluate and validate the 2 respective models, we attempted to replicate the study designs of each; thus, the final sample sizes and variable definitions for the validation sets differed according to the study-specific criteria described previously. For the purposes of this study, women in the Mayo BBD cohort with a screening mammogram 24 months before biopsy were considered eligible for the BCSC model.
Risk Models
Risk variables for the BCSC model include the following: age, pathologic diagnosis (NP, PDWA, AH, or LCIS), BI-RADS breast density (discussed later), 12 race (white nonHispanic, black non-Hispanic, Asian, Native Hawaiian, Pacific Islander, American Indian, Alaskan Native, Hispanic, other, mixed, or unknown), and number of firstdegree relatives with BC (0, 1 or more, or unknown). The BBD-BC model includes the following: age, pathologic diagnosis (NP, PDWA, or AH), number of foci of AH (0, 1, 2, or 3 or more), lobular involution (none, partial, or complete), radial scars (absent or present), combined variable of sclerosing adenosis (SA) or columnar cell alteration (CCA; present or absent), age of first live birth and number of children combined (<21 years and 1 or more children, 21 years and 3 or more children, 21 years and 1 or 2 children, or nulliparous), and family history of BC (none or any family history in first-to third-degree relatives).
Histologic Examination
Pathologic variables were assessed by an experienced study pathologist (D.W.V.) during a histologic review of archived hematoxylin and eosin slides from BBD diagnoses. Benign breast lesions were categorized with the criteria of Dupont and Page as NP, PDWA, or AH. [13] [14] [15] If there were multiple diagnoses for a single biopsy or multiple biopsies were performed, the most severe diagnosis was assigned. Individual histologic components, including SA, CCA, radial scars (present or absent), and the number of AH foci, were also determined. The extent of lobular involution was evaluated in the normal background breast lobules and classified as no involution (0% terminal duct lobular units involuted), partial (1%-74% involuted), or complete (75% involuted). 16 
Breast Density
The clinical BI-RADS 4-category tissue composition assessment was obtained from mammograms performed within the 24 months before the BBD diagnosis. During the 1997-2001 period, the third edition of the American College of Radiology BI-RADS was used, and the breast density was classified into 1 of 4 categories: entirely fat, scattered fibroglandular densities, heterogeneously dense, or extremely dense. 12 This rating has shown moderate interobserver reliability. 17 
Statistical Analysis
Variables from both models were summarized with frequencies and percentages for categorical variables and with medians and ranges for continuous variables. We compared subjects in the BBD cohort during the study period (1997-2001) with and without a mammogram, and we used chi-square and Kruskal-Wallis tests of significance for categorical and continuous variables, respectively. Similar comparisons were made across unaffected women, those with invasive BC, and those with DCIS.
Follow-up was calculated as the number of days from benign biopsy to the first occurrence of invasive BC, DCIS, death, prophylactic mastectomy, reduction mammoplasty, LCIS, or last contact. To be consistent with the methods used during each model's development, DCIS was treated as a censoring event when we were estimating risk with the BCSC model but as an outcome when we were using the BBD-BC model.
Both models were examined with the sample of women with a screening mammogram. For the BBD-BC model, the entire cohort during the 1997-2001 period was also examined because breast density is not required in this model. Individual 5-and 10-year risk predictions were calculated with both models. Each model's ability to predict the total number of events (calibration) and distinguish future cases from controls (discrimination) was assessed.
Calibration was defined as the ratio of predicted-toobserved events, with the number of observed events equaling the total number of events. The number of predicted events was estimated with methods described by Crowson et al. 18 Briefly, the predicted risk was transformed with the following formula:
Minimum ðDuration of follow-up; End of time intervalÞ End of time interval (1) We estimated the number of predicted events by taking the sum of the transformed risk value on the basis of the study sample, and we calculated the confidence interval (CI) with bootstrapping methods 19 on the basis of the number of predicted events. Discrimination was evaluated with the concordance statistic (the c statistic), a measure ranging from 0 to 1.0 that is used to evaluate the probability that a random case has a higher estimated risk than a random control. A value of 0.5 means that the model predicts the outcome no better than chance; 1.0 means perfect discrimination. The time to event was modeled in 2 ways: 1) right-censoring BC events at 5 and 10 years and 2) using Cox proportional hazards regression with the predicted risk from each model as the independent variable. The proportional hazards assumption was verified for each model.
The proportion of women classified with a high absolute risk was estimated with each of the 2 models with a priori selected thresholds of 3% for 5-year risk 20 and 8% for 10-year risk. 21 The c statistic and the corresponding CI were obtained from the coxph function with the survival package in R. 22 All remaining analyses were performed with SAS statistical software (version 9.4).
RESULTS
Study Population
Of the 2142 women from the Mayo Clinic's BBD cohort in 1997 to 2001, 1211 (56.5%) had a screening mammogram 24 months before BBD, 409 (19.1%) had only a diagnostic mammogram during this period, 15 (0.7%) had a mammogram more than 24 months before BBD, 240 (11.2%) had a screening/diagnostic mammogram only after the BBD diagnosis, and 267 (12.5%) had no mammogram available. Of the 1211 with a screening mammogram 24 months before BBD, 1089 were aged 35 to 74 years and were eligible for the BCSC model. Women with a screening mammogram had longer follow-up (median, 13.5 vs 11.4 years), were older at initial biopsy (median, 53 vs 47 years), and had higher proportions of AH (11.9% vs 6.8%), complete involution (42.1% vs 36.9%), and CCA/SA (49.5% vs 37.6%) than those without one (Table 1) .
In the overall cohort, 162 invasive or in situ cancers were observed over the median follow-up of 6.7 years. The median follow-up of unaffected and BC cases was 12.4 years. In the screening cohort, 74 invasive BC cases were observed over a median follow-up of 6.9 years, and Original Article Table 2 ). The same associations were observed when women with DCIS were grouped with women with invasive BC and were compared with the unaffected.
Performance of the BCSC Model
Among the eligible screening cohort, fifty-four invasive cases of BC were diagnosed within 10 years of follow-up, with 20 occurring within 5 years and the remaining 34 occurring between 5 and 10 years ( Table 3 ). The median 5-year risk predicted with the BCSC model was 2.7% for invasive cancers and 2.2% for unaffected/DCIS cases ( Fig. 1A and Table 2 ). At 10 years, the median BCSCpredicted risks for invasive cancers and unaffected/DCIS cases were 5.6% and 4.7%, respectively. Five years after biopsy, the BCSC model achieved a discrimination that was not statistically better than chance (c statistic, 0.59; 95% CI, 0.46-0.71), and it slightly overestimated the number of events by 31% (predicted-to-observed ratio, 1.31; 95% CI, 0.94-2.25), although there was no statistical difference because the CI contained 1.0. At 10 years, the calibration was excellent (0.94; 95% CI, 0.85-1.43), and the c statistic was now significantly better than 0.5 (0.63; 95% CI, 0.56-0.71) suggesting improved performance in comparison with 5 years.
Performance of the BBD-BC Model in the Screening Cohort and Full Cohort
The BBD-BC model performed similarly well in the mammographic screening cohort 5 and 10 years after biopsy (Table 3 ). There were 27 events (DCIS and invasive cancer) at 5 years and an additional 42 cancers between 5 and 10 years. The calibration was 1.11 (95% CI, 0.84-1.77) at 5 years, with a c statistic of 0.69 (95% CI, 0.58-0.80). At 10 years, the calibration was slightly underestimated at 0.83 (95% CI, 077-1.20) but was not statistically significant, and the c statistic was 0.66 (95% CI, 0.59-0.73; Table 3 ). The median 5-year predicted risk with the BBD-BC model was 3.0% for women who developed DCIS/invasive cancer and 2.1% for unaffected women. The median 10-year predicted risk estimates were 5.9% and 4.3%, respectively (Fig. 1B and Table 2 ).
In the entire cohort of 2142 women with BBD between 1997 and 2001, there were 56 cancers within 5 years and 62 additional cancers between 5 and 10 years (for 118 total). The performance of the BBD-BC model in the overall cohort was generally similar to its performance in the screening cohort; however, the calibration for 10-year risk showed greater evidence of an underestimation of predicted risk in the overall cohort. In the overall cohort, the calibration of the BBD-BC model was 0.89 (95% CI, 0.71-1.21) at 5 years, and the c statistic was 0.68 (95% CI, 0.60-0.75). At 10 years, the calibration was 0.81 (95% CI, 0.70-1.00), and the c statistic was 0.66 (95% CI, 0.60-0.71; Table 3 ). The median 5-year predicted risk with the BBD-BC model was 2.5% for women who developed DCIS/invasive cancer and 1.8% for unaffected women. The median 10-year predicted risk estimates were 5.0% and 3.8%, respectively (Fig. 1C) .
Estimated Absolute BC Risks Predicted by the BCSC and BBD-BC Models
Thresholds of absolute risk of cancer can be used to classify women at the greatest risk for BC and to define those who may receive the greatest benefit from prevention strategies. 20 The BCSC model predicted that 31.6% (344 women) exceeded a 5-year risk of 3%, and 13.1% (143 women) were above a 10-year risk of 8% ( Fig. 1 and Supporting Table 1 ). Of the 344 women with a 5-year risk above the 3% threshold, 2.6% developed invasive BC within 5 years; 10.5% of the 143 women with a 10-year risk above 8% developed invasive BC within 10 years. When the BBD-BC model was used in the screening cohort, a similar proportion of women (31.1% or 339) exceeded a 5-year risk of 3%, and of the 339 women predicted to be at high risk, 4.4% developed DCIS or invasive cancer during the 5 years. According to 10-year risk predictions, 194 women (17.8%) were at high risk, and 12.4% of these women developed cancer.
When we examined the BBD-BC model for all women with BBD diagnosed between 1997 and 2001, 523 women (24.4%) had a predicted risk above the 3% threshold. Of these 523 women, 4.8% developed DCIS or invasive BC within 5 years. Similarly, at 10 years, 295 women (13.8%) had a predicted risk above the threshold of 8%, and 10.5% of these women were diagnosed with cancer within 10 years.
DISCUSSION
More than 1 million women have BBD each year, which places them at greater risk for BC in comparison with the general population. 2 Women with BBD require counseling regarding their risk, and models appropriate to the BBD population are needed. We evaluated the updated BCSC and BBD-BC models for the prediction of BC risk at 5 and 10 years of follow-up in a cohort of women with BBD. We found that the BCSC model correctly predicted the number of events 5 years after biopsy but had low discrimination (no different than chance). However, at 10 years, discrimination was higher, and the calibration remained accurate. In the overall cohort and the screening cohort (with mammograms), the BBD-BC model performed well at 5 years but underestimated events at 10 years in the entire cohort, although this was only borderline statistically significant. Importantly, this study was performed on a subset of the Mayo Clinic BBD cohort that was mutually exclusive of the prior BBD-BC model development and validation sets. To our knowledge, this is the first study to examine the performance of these models in a cohort of women with BBD.
Other than age and BBD diagnosis, the BCSC and BBD-BC models share few risk factors. The BBD-BC model includes 4 histologic assessments of the biopsy based on expert review, whereas the BCSC model includes the final pathologic diagnosis from reports. The BCSC model includes BI-RADS density and race, whereas the BBD-BC model incorporates neither, although the Mayo population is primarily white. 10 Furthermore, the BBD-BC model includes a more extensive family history of BC (first to third degree) than the BCSC model (first degree). Finally, the treatment of LCIS differed.
In addition to risk factors, the models differ in their initial development population. The BBD-BC model was developed and validated with women with a confirmed BBD diagnosis, regardless of prior breast screening or breast density availability. It is intended for use in woman with a benign biopsy resulting from a screening abnormality or palpable concern and at the time of the BBD diagnosis. 7 The BCSC model, though, was initially developed for women with screening mammography and was later expanded to include findings on benign biopsies, but it was never validated in this latter population. 8 Because of the requirement for a breast density measure, the BCSC model is intended for women with an available mammogram.
The 2 models performed differentially at 5 and 10 years. Five years after biopsy, the BCSC model had lower discrimination than it did at 10 years, whereas the BBD-BC model showed underestimation of observed events (calibration) in the entire cohort at 10 years. Although we cannot make a direct comparison of the models because of the differential treatment of LCIS and DCIS in the development of the models, the higher model discrimination and calibration for the BBD-BC model at 5 years could suggest that histologic aspects might better inform shorter term risk and/or contribute to DCIS prediction for women with BBD.
Using the 5-year risk prediction from the 2 models, we found that approximately 31% of women with screening mammograms exceeded our a priori defined threshold of 3%, which was defined by the US Prevention Services Task Force as the threshold for women who receive the maximum benefit from chemoprevention. 20 Of the 31% identified as high-risk, 2% to 4% developed cancers that may have been avoided with chemoprevention. At 10 years of follow-up, 13% to 18% of women would have been offered prevention, and 11% to 12% of such women would have developed cancer. However, 1% to 5% of women at lower risk (under 3% 5-year risk or under 8% 10-year risk), who constituted the majority of women, also developed cancer. Clearly, an improvement in models for women with BBD is necessary.
There are several strengths to this study, including the evaluation of these models in a well-annotated cohort with long-term follow-up. All women had their pathology reviewed by the same experienced breast pathologist, who was masked to the later BC status. In addition, the subcohort used in this study was independent of the development sets for both models and thus provided external validation. The Mayo Clinic's unified medical record, tumor registry database, and questionnaires of study participants provided detailed information on clinical and demographic attributes and postbiopsy follow-up for cancer events. This work provides external evaluation for 2 recently published models. [7] [8] [9] We also recognize that there are limitations to this work. First, we were unable to directly compare the 2 models because of differences in BC outcomes; that is, DCIS was not included in the BCSC model. Next, our work focused on examining the BCSC and BBD-BC models because of their inclusion of histologic findings on biopsy, and we did not examine other risk models in this setting. Furthermore, only women aged 35 to 74 years with a screening mammogram up to 24 months before BBD (51% of the entire cohort) were included when we analyzed the screening cohort because of BCSC eligibility. We also had incomplete ascertainment because 9% of our sample left the Mayo Health Care System or did not respond to a questionnaire during the 10-year follow-up period. However, 95% of the women had at least 5 years of follow-up, so the misclassification of endpoints should have minimally affected model performance at 5 years. Importantly, the BCSC model was developed in a multiethnic population, whereas the BBD study sample was not racially diverse.
Finally, we acknowledge that the women in this study were more similar to the development set of the BBD-BC model than the BCSC model because they were sampled from the same population cohort with the same eligibility criteria and at the time of biopsy. Although the study sample in this work was mutually exclusive from the women used to develop the BBD-BC model, the samples were read by the same pathologist (D.W.V.) in this more recent cohort. The demographic characteristics were likely more similar to samples used to develop the BBD-BC model than the study sample used to create the BCSC model. If the same examination were made with the same population, biopsies, and pathologies from the BCSC model, it is possible that the BCSC would have had higher discrimination.
In conclusion, the BCSC model was validated in the Mayo BBD cohort and performed well 10 years after biopsy, whereas the BBD-BC model showed better performance at the 5-year time point. More study is needed to more accurately predict BC risk in women with BBD.
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